Categories
Change Password!
Reset Password!
Age does not affect bDMARDs withdrawal due to adverse events in elderly and non-elderly rheumatoid arthritis patients.
As per the results of a recent study published in the journal ‘Medicine (Baltimore)’ the rate of discontinuation of biologic disease-modifying antirheumatic drugs (bDMARDs) due to adverse events (AEs) did not vary significantly between patients younger than 75 years and patients aged 75 years and older.
Yuzo Ikari et al. assessed whether the age of rheumatoid arthritis (RA) patients was linked with AEs due to bDMARDs in this retrospective cohort study.
To solve the basis of the study, 416 RA patients (84.6% women) were registered. A comparison of outcomes in patients elder than and younger than 75 years of age was done with a maximum observation period of 1 year. The Pearson's chi-squared test and logistic regression analysis were used to accomplish the univariate and multivariate analyses.
The results primary outcome of the study is being illustrated in the following table:
Medicine (Baltimore)
The association between age and adverse events due to biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A retrospective cohort study
Yuzo Ikari et al.
Comments (0)